Company, Breast Cancer Community Join to Raise Awareness of Metastatic Disease
Reprint from Pfizer World
Pfizer works with community leaders to expand dialogue to include metastatic breast cancer.
Metastatic breast cancer affects from 150,000 to 250,000 people in the United States.
Pfizer recently surveyed people in the U.S. to learn more about their awareness of the disease – the most advanced stage (Stage IV) of the cancer, in which it has spread beyond the breast to other organs and remains uncurable. The findings revealed that many know little to nothing.
This month, Pfizer is joining with leaders in the breast cancer community in a public call to action to change the breast cancer conversation to include metastatic cancer. With patient advocates, health care professionals, and academic linguists, Pfizer has undertaken the Breast Cancer: A Story Half Told initiative to fill in the gaps in the breast cancer conversation within society and between patients and physicians, which is currently focused on early detection and survivorship, leaving patients with metastatic cancer feeling misunderstood and isolated from the larger community.
“Metastatic breast cancer is a diagnosis that can come with complicated treatment decisions,” said Executive Vice President and Chief Medical Officer Freda Lewis-Hall. “Furthermore, the emotional toll of metastatic disease can be profound, and can affect how people feel about themselves, communicate with others, and live their lives. Along with our partners, we believe that we can do more to educate about the current gaps in conversations about metastatic breast cancer and help empower those living with the disease to play a more active role in understanding their prognosis and their options for treatment.”